Hangzhou Tigermed Consulting Co., Ltd. Class H (5HZ1) Receives a Buy from CitiTip Ranks·Jul 22 at 07:27 PM033470.00%3003470.00%
UBS: CN CRO Sees Solid Revenue Growth in 1H; WUXI APPTEC Top PickAASTOCKS News·Jul 14 at 02:56 AM02269+1.42%02359+3.40%
UBS' Investment Ratings and TPs on CRO Stocks (Table)AASTOCKS News·Jul 14 at 02:00 AM3007590.00%02268+1.89%
Hangzhou Tigermed files HKEX next-day disclosure reporting share repurchasePUBT·Jun 25 at 03:42 AM3003470.00%033470.00%
Hangzhou Tigermed files HKEX next-day disclosure return on share buyback cancellationPUBT·Jun 22 at 03:34 AM3003470.00%033470.00%
Hangzhou Tigermed files HKEX next-day disclosure return on share repurchasePUBT·Jun 18 at 03:50 AM033470.00%3003470.00%
Tigermed received a Wind ESG A rating, with a comprehensive score of 7.63同壁财经·Jun 3 at 05:50 AM033470.00%3003470.00%
TIGERMED Falls 3% by Midday to Near One-Year Low After JPM Cuts TP to HKD39AASTOCKS News·May 18 at 11:28 PM033470.00%3003470.00%
TIGERMED Plans to Spend Up to RMB1B to Repurchase A SharesAASTOCKS News·May 13 at 08:44 PM3003470.00%033470.00%
Hangzhou Tigermed Unveils Up to RMB1 Billion A-Share Buyback PlanTip Ranks·May 13 at 09:38 AM3003470.00%033470.00%
Citi: TIGERMED CONSULTING Fundamentals Unaffected; Share Price Weakness Seen as Entry PtAASTOCKS News·May 13 at 03:33 AM3003470.00%033470.00%
TIGERMED Opens 6.6% Lower as Directors and Controlling Shareholders Placed Under InvestigationAASTOCKS News·May 12 at 08:38 PM033470.00%
Antibody discovery platform Immunocan closes RMB250 million Series ATechNode·May 12 at 09:39 PM3003470.00%5606000.00%
